BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University)

N/A

Report date: 2025/06/09 20:00:12

Base Information

Drug NameBCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University)
Drug Alias NameAutologous BCMA CAR-T cells and CD19 CAR-T cells
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsAnti-BCMA
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesThe First Affiliated Hospital Of Nanchang University
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Nanchang University
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A